| 杨甜,黄燕妮,吴志训,等.西格列他钠治疗2型糖尿病合并代谢相关脂肪性肝病的作用机制及临床研究进展[J].中国临床保健杂志,2026,29(3):409-413. |
| 西格列他钠治疗2型糖尿病合并代谢相关脂肪性肝病的作用机制及临床研究进展 |
| Mechanism of action and clinical research progress of chiglitazar in the treatment of type 2 diabetes mellitus complicated with metabolic dysfunction-associated fatty liver disease |
| 投稿时间：2025-10-22 |
| DOI：10.3969/J.issn.1672-6790.2026.03.022 |
| 中文关键词: 糖尿病,2型 脂肪肝 过氧化物酶体增殖物激活受体 综述 |
| 英文关键词: Diabetes mellitus,type 2 Fatty liver Peroxisome proliferator-activated receptors Review Fund programs:Hunan Provincial Natural Science Foundation Project |
| 基金项目:湖南省自然科学基金项目 |
|
| 摘要点击次数: 175 |
| 全文下载次数: 79 |
| 中文摘要: |
| 2型糖尿病(T2DM)与代谢相关脂肪性肝病(MAFLD)共存加剧了肝纤维化和心血管疾病风险。过氧化物酶体增殖物激活受体(PPAR)泛激动剂西格列他钠通过调控糖脂代谢及减轻炎症反应,成为潜在治疗选择。本文综述了西格列他钠的作用机制,并基于相关临床试验分析其单药与联合治疗的疗效及安全性,旨在为优化西格列他钠治疗T2DM合并MAFLD提供理论依据。 |
| 英文摘要: |
| The coexistence of type 2 diabetes mellitus (T2DM) and metabolic dysfunction-associated fatty liver disease (MAFLD) aggravates the risk of liver fibrosis and cardiovascular disease.Peroxisome proliferators-activated receptors (PPAR) pan agonist sitagliptin sodium has become a potential therapeutic option by regulating glucose and lipid metabolism and reducing inflammatory responses.This article reviews its molecular mechanism and analyzes the efficacy and safety of monotherapy and combination therapy based on relevant clinical trials,the aim is to provide a theoretical basis for optimizing the treatment of T2DM with MAFLD using sitagliptin. |
|
查看全文
|
| 关闭 |